<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873377</url>
  </required_header>
  <id_info>
    <org_study_id>20140019</org_study_id>
    <secondary_id>1R21CA202993-01A1</secondary_id>
    <nct_id>NCT02873377</nct_id>
  </id_info>
  <brief_title>Smoking Cessation in Hispanic Construction Workers</brief_title>
  <official_title>A Novel Worksite Smoking Cessation Intervention for Hispanic Construction Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Construction workers have the highest rate of smoking among all occupations, and are
      frequently exposed to a wide range of workplace hazards (e.g. toxins), which interact with
      smoking to increase their health risks. Minority construction workers, in particular, have
      higher smoking and lower cessation rates compared to other groups, and they generally show
      lower access and participation in cessation and health promotion services. The number of
      Hispanic workers employed in the construction industry in the US has tripled in the past
      decade to 2.6 million (23% of all construction workers). This study will develop, administer,
      and evaluate a novel smoking cessation program in a hard-to-reach and underserved population
      of Hispanic male construction workers using using pilot cluster randomized clinical trial
      (RCT) to test the developed intervention for feasibility and potential efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-arm, cluster-randomized controlled trial will be conducted with up to 15 construction
      sites, selected from one Construction Company in south Florida. Cluster randomization is used
      with construction site chosen as the unit of allocation because it is most practical in this
      setting and minimizes the risk of spillover effects from the intervention to the control
      group. In conjunction with the site's safety manager, the investigators will recruit 9 adult
      Hispanic construction workers per site (126 total) who smoke ≥5 cigarettes/day in the last
      year. Participants in the enhanced care will receive one culturally adapted brief
      face-to-face behavioral counseling session developed in phase 1 and delivered at a lunch
      truck, two brief follow-up phone counseling calls, fax referral to the Florida quitline (QL),
      and provision of up to 6 weeks of free NRT. Participants in the standard care will receive
      fax referral to the Florida QL, and provision of up to 8 weeks of free NRT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2017</start_date>
  <completion_date type="Actual">October 11, 2018</completion_date>
  <primary_completion_date type="Actual">October 11, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study arms will be conducted simultaneously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged Abstinence Rates</measure>
    <time_frame>6-month</time_frame>
    <description>Prolonged abstinence is defined as no smoking, not even a puff, after a grace period of two weeks after quit date. This will be assessed in follow up questionnaire and confirmed with saliva cotinine level of &lt;15 ng/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>7-day Point- Prevalence Prolonged Abstinence Rate</measure>
    <time_frame>6-month</time_frame>
    <description>Point prevalence abstinence rates is defined as self report of not smoking; in the past 7 days not even a puff) confirmed by saliva cotinine level of &lt;15ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enrollment Rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Enrollment rate will be reported as the percentage of participants that were eligible and randomized against the participants screened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quitline Response Rate</measure>
    <time_frame>6-month</time_frame>
    <description>Quitline Response will be reported by the percentage of participants that contacted the Quitline, enrolled in the tobacco Quitline and the participants that completed at least 1 phone call from Tobacco Quitline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-Up Rate</measure>
    <time_frame>3-month, 6-month</time_frame>
    <description>Follow up rate will be reported as the percentage of participants that completed their follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Response Rate</measure>
    <time_frame>6-month</time_frame>
    <description>Questionnaire response rate will be reported by the percentage of participants that completed the initial and follow up questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Compliance to Intervention</measure>
    <time_frame>6-month</time_frame>
    <description>Rate of compliance to intervention is reported as the percentage of participants who self-reported following intervention components at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Cigarettes Smoked</measure>
    <time_frame>Baseline, 6-month</time_frame>
    <description>For the participants that did not quit, the change in number of cigarettes smoked will be reported as the number of cigarettes smoked per day at the 6 months follow up visit minus the number of cigarettes smoked per day at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Enhanced Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the &quot;Enhanced Care&quot; intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The &quot;Standard Care&quot; group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorette Gum</intervention_name>
    <description>GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)</description>
    <arm_group_label>Enhanced Care</arm_group_label>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicoderm CQ</intervention_name>
    <description>GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)</description>
    <arm_group_label>Enhanced Care</arm_group_label>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smoking Quitline Referral</intervention_name>
    <description>Fax referral to the State smoking Quitline</description>
    <arm_group_label>Enhanced Care</arm_group_label>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>Quitline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Smoking Cessation Counseling</intervention_name>
    <description>One time face-to-face smoking cessation counseling and follow-up phone call</description>
    <arm_group_label>Enhanced Care</arm_group_label>
    <other_name>Counseling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hispanic

          -  Construction worker

          -  Have smoked ≥ 5 cigarettes/day in the past year.

          -  Have access to telephone

          -  Have no plans to move in the next six months

          -  Are interested in making a serious quit attempt in the next 30 days

          -  Have no contraindication to NRT (e.g., history of hypersensitivity to nicotine, recent
             (past month) myocardial infarction, any history of serious arrhythmias or unstable
             angina pectoris, chronic dermatological disorder (e.g., psoriasis)).

        Exclusion Criteria:

          -  Inability to understand consent procedures

          -  Not Hispanic

          -  Not a construction worker

          -  Haven't smoked ≥ 5 cigarettes/day in the past year.

          -  No access to telephone

          -  Has plans to move in the next six months

          -  Not interested in making a serious quit attempt in the next 30 days

          -  Has a contraindication to NRT

          -  Has a generalized chronic dermatological disorder (e.g., psoriasis)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taghrid Asfar, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Building University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <results_first_submitted>October 3, 2019</results_first_submitted>
  <results_first_submitted_qc>October 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2019</results_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>David Lee, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hispanics</keyword>
  <keyword>Construction workers</keyword>
  <keyword>Tobacco Quitline</keyword>
  <keyword>Nicotine replacement therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02873377/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enhanced Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period Title 2: 3 Months Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period Title 3: 6 Months Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enhanced Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="1.5"/>
                    <measurement group_id="B2" value="38.2" spread="1.4"/>
                    <measurement group_id="B3" value="39.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prolonged Abstinence Rates</title>
        <description>Prolonged abstinence is defined as no smoking, not even a puff, after a grace period of two weeks after quit date. This will be assessed in follow up questionnaire and confirmed with saliva cotinine level of &lt;15 ng/ml.</description>
        <time_frame>6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence Rates</title>
          <description>Prolonged abstinence is defined as no smoking, not even a puff, after a grace period of two weeks after quit date. This will be assessed in follow up questionnaire and confirmed with saliva cotinine level of &lt;15 ng/ml.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00"/>
                    <measurement group_id="O2" value="30.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Point- Prevalence Prolonged Abstinence Rate</title>
        <description>Point prevalence abstinence rates is defined as self report of not smoking; in the past 7 days not even a puff) confirmed by saliva cotinine level of &lt;15ng/ml.</description>
        <time_frame>6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point- Prevalence Prolonged Abstinence Rate</title>
          <description>Point prevalence abstinence rates is defined as self report of not smoking; in the past 7 days not even a puff) confirmed by saliva cotinine level of &lt;15ng/ml.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00"/>
                    <measurement group_id="O2" value="30.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enrollment Rate</title>
        <description>Enrollment rate will be reported as the percentage of participants that were eligible and randomized against the participants screened.</description>
        <time_frame>Baseline</time_frame>
        <population>Number of workers screened</population>
        <group_list>
          <group group_id="O1">
            <title>All Workers Available - Before Randomization</title>
            <description>All workers on constructions screened for eligibility</description>
          </group>
        </group_list>
        <measure>
          <title>Enrollment Rate</title>
          <description>Enrollment rate will be reported as the percentage of participants that were eligible and randomized against the participants screened.</description>
          <population>Number of workers screened</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eligible Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Randomized participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quitline Response Rate</title>
        <description>Quitline Response will be reported by the percentage of participants that contacted the Quitline, enrolled in the tobacco Quitline and the participants that completed at least 1 phone call from Tobacco Quitline.</description>
        <time_frame>6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Quitline Response Rate</title>
          <description>Quitline Response will be reported by the percentage of participants that contacted the Quitline, enrolled in the tobacco Quitline and the participants that completed at least 1 phone call from Tobacco Quitline.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Contacted by tobacco Quitline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enrolled in tobacco Quitline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.23"/>
                    <measurement group_id="O2" value="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed at least 1 phone calls from tobacco QL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08"/>
                    <measurement group_id="O2" value="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-Up Rate</title>
        <description>Follow up rate will be reported as the percentage of participants that completed their follow up visit.</description>
        <time_frame>3-month, 6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-Up Rate</title>
          <description>Follow up rate will be reported as the percentage of participants that completed their follow up visit.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.15"/>
                    <measurement group_id="O2" value="68.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.92"/>
                    <measurement group_id="O2" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Questionnaire Response Rate</title>
        <description>Questionnaire response rate will be reported by the percentage of participants that completed the initial and follow up questionnaire.</description>
        <time_frame>6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Questionnaire Response Rate</title>
          <description>Questionnaire response rate will be reported by the percentage of participants that completed the initial and follow up questionnaire.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>completed initial questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.85"/>
                    <measurement group_id="O2" value="88.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed follow-up questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.92"/>
                    <measurement group_id="O2" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Compliance to Intervention</title>
        <description>Rate of compliance to intervention is reported as the percentage of participants who self-reported following intervention components at follow-up.</description>
        <time_frame>6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Compliance to Intervention</title>
          <description>Rate of compliance to intervention is reported as the percentage of participants who self-reported following intervention components at follow-up.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Counseling session + 2 phone calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.08"/>
                    <measurement group_id="O2" value="88.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks NRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.85"/>
                    <measurement group_id="O2" value="88.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Quitline counseling sessions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks NRT from Quitline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38"/>
                    <measurement group_id="O2" value="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Cigarettes Smoked</title>
        <description>For the participants that did not quit, the change in number of cigarettes smoked will be reported as the number of cigarettes smoked per day at the 6 months follow up visit minus the number of cigarettes smoked per day at baseline</description>
        <time_frame>Baseline, 6-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Cigarettes Smoked</title>
          <description>For the participants that did not quit, the change in number of cigarettes smoked will be reported as the number of cigarettes smoked per day at the 6 months follow up visit minus the number of cigarettes smoked per day at baseline</description>
          <units>Cigarettes smoked per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="1.5"/>
                    <measurement group_id="O2" value="-11.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enhanced Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling &amp; Smoking Quitline Referral. Participants in the “Enhanced Care” intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline
Behavioral Smoking Cessation Counseling: One time face-to-face smoking cessation counseling and follow-up phone call</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The “Standard Care” group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.
Nicorette Gum: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Nicoderm CQ: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Smoking Quitline Referral: Fax referral to the State smoking Quitline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taghrid Asfar</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-3826</phone>
      <email>tasfar@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

